Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
Haryana Blog/10359761
Trending...
- OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
- Technical Brief Examines Enterprise Integration Challenges as AI Agent Platforms Expand
- New Omega-3 Fish Oil Under NIH Investigation: What Makes It Different From EPA and DHA?
As fentanyl continues to drive an enormous public-health challenge in the United States, Nutriband's AVERSA™ technology is being developed to address a different but important piece of the problem: abuse, misuse, diversion and accidental exposure involving prescription fentanyl patches
ORLANDO, Fla. - HaryanaBlog -- The fentanyl crisis remains one of America's most serious public-health challenges. While recent national data show meaningful improvement, the scale of the problem remains enormous. According to the CDC, 47,735 U.S. overdose deaths in 2024 involved synthetic opioids other than methadone, a category that includes fentanyl and fentanyl analogs.
Importantly, there are two very different fentanyl problems. Illicitly manufactured fentanyl is responsible for the majority of fentanyl-related harms, while pharmaceutical fentanyl remains an important medication used for severe pain. The CDC notes that pharmaceutical fentanyl can be prescribed in transdermal patches and that those patches can be diverted for misuse.
That second issue is where Nutriband Inc. (N A S D A Q: NTRB) $NTRB is attempting to make a difference.
AVERSA™: Targeting Abuse and Accidental Exposure
Nutriband's lead development program is AVERSA™ Fentanyl, an abuse-deterrent transdermal fentanyl system designed to incorporate Nutriband's proprietary AVERSA™ technology into a fentanyl patch.
The company's technology is intended to incorporate aversive agents into transdermal patches to help deter abuse, misuse, diversion and accidental exposure while maintaining access to the medication for patients who legitimately require it.
That distinction is critical.
Nutriband is not claiming to solve the illicit fentanyl crisis by itself. Instead, its potential contribution is focused on improving the safety profile of legitimate pharmaceutical transdermal medications that contain fentanyl or other drugs with abuse potential.
More on Haryana Blog
And that could address a meaningful, preventable portion of fentanyl-related harm.
A Look Inside America's Fentanyl Crisis
A new video examining the fentanyl crisis across the United States also features Nutriband CEO Gareth Sheridan.
The video's description explains:
"In this video I travel across the United States to investigate the fentanyl crisis that is destroying major cities across America. I speak with journalist and fentanyl researchers like Gareth Sheridan (CEO of Nutriband) to discover what is taking place in each major city from Portland, Seattle, LA and Philadelphia."
Watch the Fentanyl Crisis Investigation Featuring Gareth Sheridan
The appearance provides another opportunity for Sheridan to discuss the broader fentanyl problem and Nutriband's approach to improving the safety of prescription transdermal fentanyl.
Why This Matters for NTRB
The potential significance of AVERSA™ goes beyond simply creating another fentanyl patch.
Nutriband has designed the technology as a platform, meaning AVERSA™ could potentially be incorporated into multiple transdermal medications with abuse potential.
The company has previously reported that its AVERSA™ technology is protected by an international intellectual-property portfolio, while AVERSA™ Fentanyl remains its lead development program. Nutriband has estimated potential peak annual U.S. sales of approximately $80 million to $200 million for the product, although that is a company estimate and not a guarantee of future sales.
The development program is also moving through the regulatory pathway. Nutriband reported completing a Type C meeting with the FDA concerning Chemistry, Manufacturing and Controls plans for AVERSA™ Fentanyl, with the company working toward an IND filing supporting a Human Abuse Potential study.
More on Haryana Blog
More recently, Nutriband announced that it received a USPTO Notice of Publication for commercial brand-name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The company said that, once allowed, it plans to submit the commercial worldwide brand name to the FDA and other international regulatory agencies.
A Different Kind of Fentanyl Opportunity
For NTRB investors, the larger story is not that Nutriband can eliminate America's fentanyl crisis. No single technology can do that.
The more specific opportunity is whether AVERSA™ can make legitimate transdermal fentanyl safer by reducing the potential for abuse, diversion and accidental exposure.
With fentanyl continuing to represent a major component of America's overdose crisis, technologies designed to reduce preventable harm remain highly relevant.
Nutriband $NTRB is attempting to bring a different tool to that fight — one focused not on illicit fentanyl itself, but on making pharmaceutical transdermal fentanyl potentially safer for patients, families and communities.
That makes the continued development of AVERSA™ Fentanyl an important story to watch as Nutriband moves toward its next regulatory and commercialization milestones.
For more information on NTRB visit: https://www.nutriband.com
Nutriband, Inc.
121 South Orange Avenue
Suite 1500
Orlando, Fl 32801
Phone: 407-377-6695
Email: info@nutriband.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Importantly, there are two very different fentanyl problems. Illicitly manufactured fentanyl is responsible for the majority of fentanyl-related harms, while pharmaceutical fentanyl remains an important medication used for severe pain. The CDC notes that pharmaceutical fentanyl can be prescribed in transdermal patches and that those patches can be diverted for misuse.
That second issue is where Nutriband Inc. (N A S D A Q: NTRB) $NTRB is attempting to make a difference.
AVERSA™: Targeting Abuse and Accidental Exposure
Nutriband's lead development program is AVERSA™ Fentanyl, an abuse-deterrent transdermal fentanyl system designed to incorporate Nutriband's proprietary AVERSA™ technology into a fentanyl patch.
The company's technology is intended to incorporate aversive agents into transdermal patches to help deter abuse, misuse, diversion and accidental exposure while maintaining access to the medication for patients who legitimately require it.
That distinction is critical.
Nutriband is not claiming to solve the illicit fentanyl crisis by itself. Instead, its potential contribution is focused on improving the safety profile of legitimate pharmaceutical transdermal medications that contain fentanyl or other drugs with abuse potential.
More on Haryana Blog
- Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
- CB Stuffer Announces Private Sale to Secure Future of Brand Growth
- The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
- Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
And that could address a meaningful, preventable portion of fentanyl-related harm.
A Look Inside America's Fentanyl Crisis
A new video examining the fentanyl crisis across the United States also features Nutriband CEO Gareth Sheridan.
The video's description explains:
"In this video I travel across the United States to investigate the fentanyl crisis that is destroying major cities across America. I speak with journalist and fentanyl researchers like Gareth Sheridan (CEO of Nutriband) to discover what is taking place in each major city from Portland, Seattle, LA and Philadelphia."
Watch the Fentanyl Crisis Investigation Featuring Gareth Sheridan
The appearance provides another opportunity for Sheridan to discuss the broader fentanyl problem and Nutriband's approach to improving the safety of prescription transdermal fentanyl.
Why This Matters for NTRB
The potential significance of AVERSA™ goes beyond simply creating another fentanyl patch.
Nutriband has designed the technology as a platform, meaning AVERSA™ could potentially be incorporated into multiple transdermal medications with abuse potential.
The company has previously reported that its AVERSA™ technology is protected by an international intellectual-property portfolio, while AVERSA™ Fentanyl remains its lead development program. Nutriband has estimated potential peak annual U.S. sales of approximately $80 million to $200 million for the product, although that is a company estimate and not a guarantee of future sales.
The development program is also moving through the regulatory pathway. Nutriband reported completing a Type C meeting with the FDA concerning Chemistry, Manufacturing and Controls plans for AVERSA™ Fentanyl, with the company working toward an IND filing supporting a Human Abuse Potential study.
More on Haryana Blog
- Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
- ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
- Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
More recently, Nutriband announced that it received a USPTO Notice of Publication for commercial brand-name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The company said that, once allowed, it plans to submit the commercial worldwide brand name to the FDA and other international regulatory agencies.
A Different Kind of Fentanyl Opportunity
For NTRB investors, the larger story is not that Nutriband can eliminate America's fentanyl crisis. No single technology can do that.
The more specific opportunity is whether AVERSA™ can make legitimate transdermal fentanyl safer by reducing the potential for abuse, diversion and accidental exposure.
With fentanyl continuing to represent a major component of America's overdose crisis, technologies designed to reduce preventable harm remain highly relevant.
Nutriband $NTRB is attempting to bring a different tool to that fight — one focused not on illicit fentanyl itself, but on making pharmaceutical transdermal fentanyl potentially safer for patients, families and communities.
That makes the continued development of AVERSA™ Fentanyl an important story to watch as Nutriband moves toward its next regulatory and commercialization milestones.
For more information on NTRB visit: https://www.nutriband.com
Nutriband, Inc.
121 South Orange Avenue
Suite 1500
Orlando, Fl 32801
Phone: 407-377-6695
Email: info@nutriband.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: CorporateAds
0 Comments
Latest on Haryana Blog
- Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
- Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
- ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!
- New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
- Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
- Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free
- Freight Broker 911 and Milton Collier Introduce "What's The 911?"—A New Podcast Built on Real Talk, Real Freight, and Real Opportunity
- PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales
- KOLBUS America, For All Of Your Hycorr Equipment And Service Needs
- Heritage at Hopewell Announces New 3.875% Year-One Mortgage Rate Buydown Incentive on Quick Delivery Townhomes (7.11% APR)
- New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
- Rent a Truck or Hire Movers? New Data Shows Fuel Now Makes Up to 40% of DIY Moving Costs
- Club Wyndham Research Identifies the "Holiday Rewind Effect": 93% of Parents Recreate Their Own Childhood Holidays for Their Kids
- IEI Rugged IP66 Panel PC Brings Real-Time Visibility to Heavy-Duty Mining Fleets
- FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
- Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
- Shelter Structures America backs MATRA Second Life Project to turn retired tent vinyl into homes for displaced families
- P-Wave Press Announces Becoming Dad: Reflections for New Fathers by L. A. Davenport
- Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
- Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup



